Small heterodimer partner (SHP, NR0B2) is an atypical orphan nuclear receptor that inhibits transcriptional activation by several other nuclear receptors. We recently reported that mutations in the SHP gene are associated with insulin resistance. In the present study, we demonstrated that the SHP gene is expressed in adipose tissues. A reporter gene assay showed that a gene product of SHP increased the transcriptional activation of peroxisome proliferator-activated receptor (PPAR) ␥. SHP-mediated activation of PPAR␥ was observed both in the presence and absence of the ligand of PPAR␥. Immunoprecipitation and glutathione S-transferase pull-down assay showed that SHP directly bound to PPAR␥ and competed with nuclear receptor corepressor for binding to PPAR␥. Serial deletion studies indicated that the C terminus of SHP is important for PPAR␥ activation. Mutant SHP proteins, which are found in naturally occurring mutation, showed less enhancing activity for PPAR␥ than wild-type SHP. Our results suggest that SHP may act as an endogenous enhancer of PPAR␥.
that contains two zinc fingers, a hinge domain that is a variable linker region and a functionally complex C-terminal region that includes the ligand-binding domain, the dimerization interface, and the ligand-dependent transactivation domain (AF-2) (1-4). These nuclear receptors regulate expression of genes that function in a variety of metabolic pathways.
Peroxisome proliferator-activated receptor (PPAR) ␥ is a transcription factor, belonging to the nuclear receptor superfamily. PPAR␥ is a master regulator for adipocyte differentiation (5, 6) and is important in regulation of a number of genes involved in fatty acid and glucose metabolism (7) (8) (9) . Synthetic PPAR␥ ligands, thiazolidinedione drugs, increase insulin sensitivity and are used in the treatment of diabetic patients (10 -12) . In contrast, individuals with a loss-of-function mutation in the PPAR␥ gene developed early-onset type 2 diabetes with severe insulin resistance (13) . Therefore, endogenous modulators of PPAR␥ should affect the insulin sensitivity.
Small heterodimer partner (SHP, NR0B2) is an atypical orphan nuclear receptor composed of 257 amino acids (human protein) or 260 amino acids (murine protein) that lacks a conventional DBD (14) . It has been reported that SHP interacts with several other nuclear receptors and modulates the transcriptional activities (14 -19) . Recently we reported that mutations in SHP gene in humans associated with insulin resistance and mild obesity (19) . The underlying mechanism by which mutations in SHP gene represented such phenotypes has been unclear. We hypothesized that SHP might affect the transcriptional activation activity of PPAR␥.
In the present study, we demonstrated that SHP up-regulated the transcriptional activity of PPAR␥ through the direct binding to the DBD/hinge region of PPAR␥. SHP inhibited the repressor activity of nuclear receptor corepressor (NCoR). The mutant SHP proteins found in the subjects with SHP mutation had decreased activation activity for PPAR␥. Our data suggest that SHP may act as an endogenous enhancer of PPAR␥.
EXPERIMENTAL PROCEDURES
Reverse Transcription-PCR-For detection of SHP mRNA, total RNA was isolated from adipose tissues of a 9-week-old male ICR mouse using TRIzol reagent (Invitrogen) according to the manufacturer's instruc-tions. Total RNA (5 g) was reverse-transcribed with Superscript preamplification system (Invitrogen) according to the manufacturer's instructions. The following forward and reverse primers were used for specific PCR amplification: SHP; 5Ј-CTGCAGGTCGTCCGACTATTC-3Ј and 5Ј-AGTGAGCCTCCTGTTGCAGG-3Ј (annealing temperature, 60°C; product size, 558 bp); ␤-actin, 5Ј-CTGGCACCACACCTTCTA-3Ј and 5Ј-GGGCACAGTGTGGGTGAC-3Ј (20) (54°C, 238 bp). PCR products were separated by electrophoresis on 2% agarose gels. The resolved DNA fragments were transferred to nylon membranes and hybridized with specific [␣-
32 P]dCTP-radiolabeled PCR products. Hybridization was performed in QuikHyb hybridization solution (Stratagene) at 65°C for 1 h, followed by washing in 0.1 ϫ SSC plus 0.1% SDS at 65°C for 15 min. Autoradiographically produced images were analyzed using a BAS-2000 system (FUJIX).
Transient Transfection Assays-The pCMV-wild-type (WT) and mutant (L98fsdel9insAC, H53fsdel10, R34X, and A195S) SHP expression vectors used in this investigation have been described previously (19) . Deletion mutants of SHP (W157X, E111X, and Q89X) with the hemagglutinin (HA) epitope at the C terminus were generated by PCR and subcloned to pCMV mammalian expression vector. Full-length human PPAR␥2 and human RXR␣ cDNAs were amplified by PCR and cloned into pcDNA3.1 (Invitrogen). Sequences of the newly generated constructs were verified. The pcDNA3.1-HNF4␣ expression plasmid and pGL3-HNF1␣ promoter reporter gene have been described previously (19) . Human ER␣ expression vector RSV-ER␣ and pUC8 -3xPPRE-tkluciferase vector, which has three copies of PPRE upstream of the TK promoter/luciferase fusion gene (21) were kind gifts from Dr. A. Kakizuka (Osaka Bioscience Institute, Japan). One copy of the estrogen response element (5Ј-AGGTCACAGTGACCTG-3Ј) was inserted upstream of the TK-luciferase gene to generate an ER␣ reporter gene. The pcDNA3.1/HisA-mouse NCoR (amino acids 1944 -2453) expression vector was a kind gift from Dr. S. Katoh (Tokyo University). CV-1 and HeLa cells were maintained in DMEM supplemented with 10% FCS, 100 l/ml penicillin, and 100 l/ml streptomycin. One day before transfection, cells were transferred to six-well plates (10 5 cells/well). Using LipofectAMINE Plus reagent (Invitrogen), cells were transfected on the next day in Opti-Mem (Invitrogen) with various amounts of expression vectors and reporter genes together with pRL (Renilla luciferase)-SV40 as an internal control. After 3 h, the medium was changed to DMEM (10% FCS) containing various ligands in Me 2 SO, or Me 2 SO alone. Transactivation activities were measured after 48 h using the Dualluciferase reporter assay system (Promega) according to the manufacturer's instructions. Renilla luciferase activity was used to normalize transfection efficiencies between experiments.
Western Analysis-One microgram of HA-tagged SHP plasmid constructs was transfected with LipofectAMINE Plus reagent into CV-1 cells in six-well plates. Forty-eight hours after transfection, cells were lysed in sample buffer (22) and subjected to 15% SDS-PAGE. The proteins were transferred to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). The membranes were incubated with rabbit polyclonal anti-HA-tagged antibody (MBL) for 2 h at room temperature and further incubated with horseradish peroxidase-conjugated antirabbit IgG antibody (New England BioLabs, Beverly, MA). Bands were visualized with ECL Western blotting detection reagents (Amersham Biosciences, Inc., Buckinghamshire, UK).
Glutathione S-Transferase Pull-down Assays-Full-length human PPAR␥2 and human RXR␣ cDNAs were cloned in-frame to the XhoI site of pGEX4T3 (Amersham Biosciences, Inc.). PPAR␥2 deletion mutants were generated by PCR and cloned in-frame in pGEX4T3. GST fusion proteins were expressed and purified from Escherichia coli BL21(DE3) using glutathione-Sepharose 4B beads (Amersham Biosciences, Inc.). SHP or NCoR proteins were synthesized using a TnT T7-coupled reticulocyte lysate system (Promega) with [ 35 S]cysteine. 35 S-Labeled proteins were incubated with ϳ1 g of GST fusion proteins in NETN (20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40) for 1.5 h at 4°C. After washing by buffer H (20 mM Hepes (pH 7.7), 50 mM KCl, 20% glycerol, 0.1% Nonidet P-40), specifically bound proteins were subjected to 15% SDS-PAGE. After electrophoresis, radiolabeled proteins were autoradiographed and analyzed using the BAS-2000 system (FUJIX). To estimate amounts of GST fusion proteins, gels were stained with Coomassie Blue.
FIG. 1.
Expression of SHP mRNA in adipose tissues. RT-PCR was performed using total RNA extracted from various mouse adipose tissues as templates, and the PCR products were subjected to cDNA Southern blotting using a probe specific for SHP (upper panel) or ␤-actin (lower panel).
FIG. 2.
Effects of SHP on transcriptional activity of nuclear receptors. A, PcDNA3.1-HNF4␣ (100 ng/well), pGL3-HNF1␣ promoter (500 ng/well), and pRL-SV40 (10 ng/well) were cotransfected with or without pCMV-SHP (100 ng/well) into CV-1 cells. B, RSV-ER␣ (500 ng/well), pUC8-ERE-luciferase (500 ng/well), and pRL-SV40 (10 ng/well) were cotransfected with or without pCMV-SHP (1 g/well) into CV-1 cells in the presence of 10 nM ␤-estradiol. C and D, PcDNA3.1-PPAR␥2 (100 ng/well), pcDNA3.1-RXR␣ (100 ng/well), pUC8 -3xPPRE-luciferase (500 ng/well), and pRL-SV40 (10 ng/well) were cotransfected with or without pCMV-SHP (100 ng/well) into CV-1 cells (C) or HeLa cells (D). Cells were transfected and cultured for the luciferase assay as described under "Experimental Procedures." Data are expressed relative to luciferase activity with luciferase reporter constructs and empty expression vector alone. Data represent the mean (n ϭ 3) Ϯ S.E. *, p Ͻ 0.05; **, p Ͻ 0.01.
Immunoprecipitation Assays-COS-7 cells (2 ϫ 10
6 ) were cotransfected with 5 g of pCMX-mouse PPAR␥, which was a kind gift from Dr. David J. Mongelsdolf, and 5 g of pCMV-SHP-HA using LipofectAMINE Plus reagent, incubated for 48 h in DMEM (10% FCS), and collected for immunoprecipitation. After washing, cells were lysed in lysis buffer containing 10 mM HEPES, pH 7.5, 142.5 mM KCl, 5 mM MgCl 2 , 1 mM EGTA, 0.2% Nonidet P-40, 1 mM Na 3 VO 4 , 10 mM NaF, 1 mM Na 2 P 2 O 7 , 1 mM phenylmethylsulfonyl fluoride, and 10 g/ml aprotinin. Lysates were preincubated with protein G-Sepharose (Amersham Biosciences, Inc.) for 1 h to eliminate nonspecific binding and incubated overnight with anti-PPAR␥ rabbit polyclonal antibody (Santa Cruz H-100), anti-HA rabbit polyclonal antibody (MBL), or non-immune rabbit serum. Immunoprecipitates were captured with protein G-Sepharose for 6 h and washed five times in lysis buffer. Immunoprecipitates were solubilized with sample buffer and subjected to SDS-PAGE and immunoblotting. SHP-HA was detected using anti-HA mouse monoclonal antibody (Roche Molecular Biochemicals clone 12CA5), and PPAR␥ was detected using anti-PPAR␥ mouse monoclonal antibody (Santa Cruz E-8).
Statistical Analysis-Statistical analyses were performed with unpaired t tests. p Ͻ 0.05 was considered to indicate significance.
RESULTS

SHP mRNA Expression in Fat
Tissues-SHP was shown to be expressed in various tissues, including liver, heart, and pancreas (14) , but the expression in adipose tissue, where PPAR␥ predominantly functioned, had not been reported. RT-PCR analyses demonstrated that SHP mRNA expressed in mouse mesenteric, epididymal, and subcutaneous fat tissues (Fig. 1) .
Effect of SHP on the Transcriptional Activity of PPAR␥-Next, we examined functional interactions of SHP with HNF4␣, ER␣, and PPAR␥ by luciferase reporter assay using CV-1 cells. As reported previously (15, 16, 19) , SHP suppressed transcriptional activities of HNF4␣ and 17␤-estradiol-activated ER␣ in CV-1 cells (Fig. 2, A and B) . However, surprisingly, SHP enhanced PPAR␥ activity both in CV-1 cells and HeLa cells (Fig. 2, C and D) . Increasing amounts of SHP expression vector (25-500 ng) increased the reporter construct activity in a dose-dependent manner (1.0-to 9.6-fold) (Fig. 3) . Enhancement of the SHP-mediated activation of PPAR␥ was also observed in the presence of troglitazone (TGZ), a synthetic ligand of PPAR␥ (1.1-to 5.4-fold).
Interaction of SHP with PPAR␥-We asked whether SHP could associate with PPAR␥ in mammalian cells. COS-7 cells were cotransfected with plasmids expressing HA-tagged SHP and PPAR␥. Lysates from these cells were subjected to immunoprecipitation using anti-PPAR␥ antibody, and immunoprecipitates were immunoblotted with anti-HA antibody (Fig. 4A,  upper panel) . The same lysates were subjected to immunoprecipitation using anti-HA antibody and were immunoblotted with anti-PPAR␥ antibody (Fig. 4A, lower panel) . These data show that SHP directly binds to PPAR␥ in mammalian cell. Furthermore, the direct interaction of SHP with PPAR␥2 was verified using a GST pull-down assay (Fig. 4B) . As described previously (16) , SHP bound to GST-RXR␣ (lane 2 versus 1), and this binding was augmented by a specific ligand, 9-cis-retinoic acid (RA) (lane 3 versus 2). On the other hand, SHP also bound to PPAR␥2 (lane 4 versus 1), but the binding between GST-PPAR␥2 and SHP was not affected by either of 10 M TGZ, pioglitazone (PGZ), or rosiglitazone (RGZ) (lanes 5-7 versus 4).
Next, to determine the domain of PPAR␥2 that mediates interaction with SHP, we generated three deletion mutants of PPAR␥2 as GST fusion proteins (Fig. 5A ) and investigated their interactions with SHP by GST pull-down assays ( 
FIG. 4. Interaction of SHP with PPAR␥.
A, plasmid pCMV-SHP-HA and pCMX-PPAR␥ were cotransfected into COS-7 cells. Cell lysates were immunoprecipitated (IP) using anti-PPAR␥ antibody or normal rabbit serum, and immunoblotting (IB) was performed with anti-HA antibody (upper panel) as described under "Experimental Procedures." Similarly, IP was performed using anti-HA antibody or normal rabbit serum, and IB was performed with anti-PPAR␥ antibody (lower panel). B, immobilized control GST protein, PPAR␥2, or RXR␣ fused to GST on glutathione-Sepharose beads was incubated with SHP in vitro translated and 35 S-labeled in the presence or absence of 9-cisretinoic acid (9-cisRA), troglitazone (TGZ), pioglitazone (PGZ), or rosiglitazone (RGZ), respectively. The GST pull-down assay was performed as described under "Experimental Procedures." All ligands concentrations are 10 M.
AF-2 domain, where other coactivators such as steroid receptor coactivator-1 (SRC-1) and CREB-binding protein were reported to bind (23) (24) (25) . The domain of PPAR␥2 interacting with SHP is similar to that interacting with PPAR␥ coactivator-1 (PGC-1) (26). We also examined the effect of SHP on the PGC-1-mediated PPAR␥ activation using luciferase reporter assay and found no additive effect between SHP and PGC-1 for PPAR␥ activation (data not shown).
NCoR, which mediates ligand-independent transcriptional repression, was reported to bind to full-length PPAR␥ in the absence of its ligand (27) . NCoR was also shown to bind to the hinge region of thyroid hormone receptor (TR) (28, 29) . However, there have been no reports on the interacting domain of PPAR␥ to NCoR. We used three deletion mutants of PPAR␥2-fused GST and investigated their interactions with NCoR (Fig.  5B, lower panel) . GST-full-length PPAR␥2 bound to NCoR (lane 8 versus 7). The AF-1 region of PPAR␥2 (amino acids 1-138) alone did not bind to NCoR (lane 9). On the other hand, amino acids 187-505 of PPAR␥2 interacted strongly with NCoR at a similar degree to full-length PPAR␥2 (lane 10). Further deletions of 41 amino acids (228 -505) showed less binding activity to NCoR (lane 11). These results suggest that the interacting domain of PPAR␥2 to NCoR includes amino acids 187-505. That is to say, the hinge domain of PPAR␥2 might be necessary for binding with NCoR. These results also suggest that the binding domain of PPAR␥2 to SHP overlaps that to NCoR.
SHP Antagonizes the Repressive Effect of NCoR on PPAR␥-
We demonstrated that SHP bound to the hinge domain of PPAR␥ in Fig. 5 . Thus, we postulated that SHP might compete with NCoR for binding to PPAR␥ and affect the repressor activity of NCoR to PPAR␥. On the assumption that SHP and NCoR share the binding site to PPAR␥, we performed a competitive binding study based on the immunoprecipitation assay (Fig. 6A) . COS-7 cells (2 ϫ 10 6 ) were cotransfected with a pCMV-SHP-HA tag (5 g) and pCMX-PPAR␥ (5 g) together with a non-tagged SHP expression plasmid (5 g), NCoR expression vector (5 g), or empty vector. As was shown in Fig. 4 , SHP directly bound to PPAR␥ (lane 3 versus 2). This signal was weakened in the presence of cold (tag) SHP (lane 4 versus 3), which indicated the specific binding of SHP to PPAR␥. NCoR expression also decreased the signal of SHP binding to PPAR␥ (lane 5 versus 3), which suggested that SHP and NCoR shared the binding region on PPAR␥. Next, we examined the effect of SHP on inhibitory activity of NCoR for PPAR␥ transactivation using luciferase reporter assay (Fig. 6B) . CV-1 cells (10 5 ) were transfected with pcDNA3.1-NCoR expression vector (0.1-1 g) together with 100 ng of PPAR␥2⅐RXR␣ and reporter gene constructs. NCoR dose dependently repressed the transcriptional activity of PPAR␥ to 51.8% (p Ͻ 0.01). When pCMV-SHP ex-
FIG. 5. Mapping a binding domain of PPAR␥2 to SHP. A, structure of full-length human PPAR␥2 and diagram of various PPAR␥2 deletions. B, SHP (upper panel), or NCoR (lower panel), in vitro translated and
35 S-labeled, was incubated with GST fused with PPAR␥2 full-length or with various deletions. GST pull-down assays were performed as described under "Experimental Procedures," and a representative blot is shown.
FIG. 6. Competitive interaction of SHP and NCoR with PPAR␥.
A, COS-7 cells were cotransfected with expression vectors indicated on the panel. 2 days later, lysates were subjected to immunoprecipitation (IP) assay as described under "Experimental Procedures." IP and immunoblotting (IB) were performed using anti-PPAR␥ antibody and anti-HA antibody, respectively. non, non-immune rabbit serum. B, CV-1 cells were transiently cotransfected with pcDNA3.1-PPAR␥2, pcDNA3.1-RXR␣, pUC8 -3xPPRE-luciferase (500 ng/well), and pRL-SV40 (10 ng/well) together with indicated amounts of NCoR and SHP expression plasmid. Reporter assay was performed as described under "Experimental Procedures." Data are expressed relative to luciferase activity with luciferase reporter constructs pcDNA3.1-PPAR␥2 and pcDNA3.1-RXR␣, and empty expression plasmid alone. All values represent the mean (n ϭ 3) Ϯ S.E. *, p Ͻ 0.01. versus luciferase activity with pcDNA3.1-PPAR␥2, pcDNA3.1-RXR␣, and empty expression constructs. ¶, p Ͻ 0.05; ¶ ¶, p Ͻ 0.01 versus luciferase activity with pcDNA3.1-PPAR␥2 and pcDNA3.1-RXR␣ and 1 g of pcDNA3.1/HisA-NCoR. pression vector (10 -100 ng) was cotransfected with 1 g of NCoR expression vector, SHP preserved the transactivation activity of PPAR␥ that had been decreased by NCoR expressed alone. Taken together, the effect of SHP on PPAR␥ activation may be partially attributed to SHP inhibition of NCoR activity.
Mapping an Activating Domain of SHP-Earlier studies of SHP have located a functional domain in the C-terminal region (amino acids 160 -260) (17) . To examine the function of the C-terminal region for PPAR␥ activities, we generated three additional C-terminal SHP deletion mutants (W157X-, E111X-, and Q89X-SHP) (Fig. 7A ) and tested their potentiality to bind and activate PPAR␥. Expression of W157X and E111X mutant proteins, at a similar amount to that of wild-type protein, was confirmed by Western analysis after transfection in CV-1 cells (Fig. 7B ), but no expression was seen for Q89X-SHP. The ability of W157X-SHP and E111X-SHP to bind GST-PPAR␥2 was confirmed by GST pull-down assay, the degree to which was similar to wild-type SHP (Fig. 7C) . PPAR␥-enhancing activity of the mutant with a 100-amino acid deletion in the C terminus (W157X-SHP) and that of E111X-SHP, which lacks an additional 46 amino acids, was reduced by 29.3% (p Ͻ 0.01) and 54.7% (p Ͻ 0.01), respectively, for comparison with WT-SHP (Fig. 6D) . These data suggest that the C-terminal region (amino acids 111-257) of SHP is important for activation of PPAR␥.
Functional Characterization of Mutant SHP Proteins-The human subjects with SHP mutation had insulin resistance (19) . The activities of mutant SHP proteins for PPAR␥ were compared with that of WT-SHP. Structures of four naturally occurring mutants of SHP are indicated in Fig. 8A . L98fsdel9insAC has a deletion of 9 bases and insertion of an AC dinucleotide at codon 98 for Leu, whereas H53fsdel10 has a deletion of 10 bases starting at codon 53 for His. R34X has a nonsense mutation at Arg codon 34 that results in termination. A195S has a replacement of Ala codon 195 by Ser. Thus, all of these mutants have an abnormal C-terminal region. Western analysis indicated that WT and mutant (H53fsdel10-, L98fsdel9insAC-, and A195S-) SHP proteins were expressed efficiently in CV-1 cells (Fig. 8B) . In contrast, no expression of R34X-SHP was detected by Western analysis. Next, we evaluated the potentiality of these mutant proteins on PPAR␥. These expressed mutant proteins had binding activities to PPAR␥, at a similar strength to WT-SHP (Fig. 8C) . CV-1 cells were transfected with 100 ng of WT or mutant SHP expression construct together with PPAR␥2⅐RXR␣ vectors and the reporter gene. PPAR␥ enhancement of activities of L98fsdel9insAC-, H53fsdel10-, and A195S-SHP was significantly reduced to 41% (p Ͻ 0.01), 47% (p Ͻ 0.01), and 57% (p Ͻ 0.01) compared with that found with WT-SHP, respectively (Fig. 8D) . The R34X mutant did not affect transactivation activity of PPAR␥, as predicted from the lack of expression. These results are consistent with the fact that the C-terminal region of SHP is FIG. 7 . Mapping an activating domain of SHP for PPAR␥. A, diagram of WT and various SHP deletion mutants. B, 1 g of pCMV-WT or SHP deletions cDNA with HA tag was transfected into CV-1 cells. Cell lysates were subjected to Western blot analysis using polyclonal anti-HA-tag antibody. C, in vitro binding of 35 S-labeled SHP deletions to GST-PPA-R␥2 was analyzed by GST pull-down assay without ligands as described in the legend of Fig. 4B . D, CV-1 cells were transiently cotransfected with pcDNA3.1-PPAR␥2, pcDNA3.1-RXR␣, pUC8 -3xPPRE-luciferase, and pRL-SV40, together with WT SHP cDNAs or SHP cDNAs with the deletions indicated, that were cloned into pCMV (100 ng/well). Reporter assay was performed as described under "Experimental Procedures." Data are expressed relative to luciferase activity with luciferase reporter constructs, pcDNA3.1-PPAR␥2, pcDNA3.1-RXR␣, and pCMV alone. All values represent the mean (n ϭ 3) Ϯ S.E. *, p Ͻ 0.01 versus WT. important for activation of PPAR␥. However, these mutants still have weak enhancing activity to PPAR␥, suggesting that the N terminus of SHP is also involved in the transactivation of PPAR␥. Insulin resistance in the subjects with SHP mutation may be partially accounted by reduced PPAR␥ activities. DISCUSSION SHP was originally cloned, by a yeast two-hybrid system, as an associate protein to mCAR, a close murine relative of the human orphan nuclear receptor MB67 (14, 30) . To date, SHP has been reported to function as a repressor of various nuclear receptors, including RAR, TR, RXR, ER, HNF4␣ and LRH-1 (14 -19) . SHP mRNA is expressed abundantly in the liver, heart, and pancreas (14) , but its transcript has been detected quite ubiquitously (15) . The effect of SHP on transactivation activity of PPAR␥ has not been evaluated. In the present study, we demonstrated that SHP mRNA is expressed in adipose tissues, in which PPAR␥ predominantly functions. Unlike other nuclear receptors, SHP increased the transcriptional activity of PPAR␥. This activation was significantly diminished in the mutant SHP proteins found in naturally occurring mutations.
The interaction of SHP with PPAR␥ was quite different from that with other nuclear receptors. In previous studies, SHP exhibited repressor activity in its C terminus and functioned by binding to the AF-2 domain of the target receptors (15) (16) (17) . In contrast, we demonstrated that SHP bound to a part of the DBD and the hinge domain of PPAR␥ and exerted enhancing activity at the C terminus. However, the precise molecular mechanism by which SHP activates the transcriptional activity of the PPAR␥⅐RXR␣ heterodimer is not clear, however, one or more of the following mechanisms might be involved: 1) SHP might directly inhibit the binding of the PPAR␥⅐RXR␣ complex to PPRE (14) . 2) SHP might compete with the corepressors for binding to PPAR␥. 3) SHP may possess its own activating function in its C terminus (17) . SHP inhibited DNA binding of RAR⅐RXR (14) but showed no effect on that of ER␣, HNF4␣, or LRH-1 (15, 16, 18) . In the present study, we were unable to demonstrate a significant effect of SHP on binding of PPAR␥⅐RXR␣ to PPRE (data not shown). SHP competes with some coactivators for binding to nuclear receptors, including SRC-3 to HNF4␣ and TIF2 to ER␣ (15, 16) . NCoR functions as a corepressor for PPAR␥. In our study, SHP competed with NCoR for binding to PPAR␥ and increased the activity. Dissociation of NCoR may cause a conformational change of PPAR␥ FIG. 8 . Functional characterization of mutant SHP proteins identified in human subjects. A, schematic structure of human SHP and SHP mutants. B, protein expression of WT or SHP mutants in transfected CV-1 cells was analyzed by Western blotting using anti-HA-tag antibody, as described in the legends of Fig.  7B . C, in vitro binding of 35 S-labeled mutant SHP proteins to GST-PPAR␥2 was analyzed by GST pull-down assay without ligands as described in the legend of Fig.  7C . D, CV-1 cells were transiently cotransfected with pcDNA3.1-PPAR␥2 (100 ng/well), pcDNA3.1-RXR␣ (100 ng/well), pUC8 -3xPPRE-luciferase (500 ng/well), and pRL-SV40 (10 ng/well), together with various SHP cDNAs cloned into pCMV (100 ng/well) as indicated. Reporter assay was performed as described under "Experimental Procedures." Data are expressed relative to luciferase activity with luciferase reporter constructs, pcDNA3.1-PPAR␥2, pcDNA3.1-RXR␣, and pCMV alone. All values represent the mean (n ϭ 3) Ϯ S.E. *, p Ͻ 0.01 versus WT.
with subsequent activation. Other mechanisms may be involved in this augmentation, because SHP still enhanced PPAR␥ activity even in the presence of its ligand, in which NCoR dissociates from PPAR␥ (27) . PGC-1 is one of the coactivators of PPAR␥ (26) . Docking of PGC-1 to the DBD/hinge domain of PPAR␥ results in a state permissive for binding of other cofactors such as SRC-1 and CREB-binding protein, followed by activation of the receptor (31) . SHP may activate PPAR␥ by a mechanism similar to PGC-1.
Our results also showed that mutant SHP proteins, found in naturally occurring mutations, had less enhancing activity for PPAR␥ than WT-SHP. All mutants have an abnormal C-terminal region. Serial C-terminal deletion mutants also showed less enhancing activity. These mutant proteins had a normal N terminus and retained the binding activity for PPAR␥. In this regard, a recent report (32) has demonstrated that the LXXLLrelated motif in the N terminus of SHP is important for binding to ER. Another atypical orphan receptor, DAX-1, which is the closest relative of SHP, also has a binding domain for nuclear receptors in the N terminus (33) (34) (35) . The C terminus of SHP may activate PPAR␥ in co-operation with the N-terminal domain. Accordingly, further investigation of the functional interaction between the N-and C-terminal regions should provide new insight into the mechanism(s) of SHP-mediated PPAR␥ transactivation. It has been reported that SHP represses the activity of the RXR homodimer to the RXRE-containing promoter (16) . Although SHP increases the activity of PPAR␥⅐RXR␣ heterodimer complex, it is possible that the mutant SHP proteins with the abnormal C terminus may have a more potent repressor activity for RXR␣ than WT, resulting in reduced activity for the PPAR␥⅐RXR␣ complex. Further studies are necessary to analyze the direct effect of SHP on the heterodimeric partner RXR␣ of the PPAR␥ complex.
Genetic mutations of SHP in human subjects are associated with insulin resistance and mild obesity (19) . Activation of PPAR␥ by its synthetic ligands increases insulin sensitivity (10 -12) . Individuals with a dominant negative mutation of the PPAR␥ gene have been reported to develop severe insulin resistance (13) . In the present study, we showed that mutant SHPs exhibit less enhancing activity on PPAR␥ than WT. These observations suggest that less enhancing activity of PPAR␥ by mutant SHP proteins may be involved in insulin resistance in subjects with SHP mutation. On the other hand, it is still not clear how SHP mutations contribute to mild obesity. SHP mutations are associated with abnormally high birth weight and early-onset obesity (19) . Because SHP inhibits the activities of various other nuclear receptors, including RAR, TR, ER, HNF4␣, and LRH-1, the clinical phenotypes of the SHP mutation cannot be accounted for only by the SHP-PPAR␥ pathway. Loss of SHP function might lead to increased activity of HNF4␣ and may increase the secretion of insulin from pancreatic ␤-cells. Because insulin is one of the key hormones involved in adipogenesis, increased insulin secretion in utero could promote intrauterine growth of adipose tissue and predispose to postnatal obesity in affected individuals.
Although detailed analysis of SHP interaction with PPAR␥ remains to be completed, our finding that SHP enhances the transcriptional activity of PPAR␥ might allow the design of new approaches to the treatment of insulin resistance syndrome. Because SHP has a putative ligand-binding domain in the C-terminal region, identification of the putative SHP ligands or agonists may allow the design of a new class of therapeutic agents to combat insulin resistance.
